Pfizer, Inc. (NYSE:PFE) Position Boosted by Regent Investment Management LLC

Regent Investment Management LLC boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 65,790 shares of the biopharmaceutical company’s stock after buying an additional 103 shares during the period. Regent Investment Management LLC’s holdings in Pfizer were worth $2,210,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of PFE. Access Financial Services Inc. boosted its stake in shares of Pfizer by 16.5% in the second quarter. Access Financial Services Inc. now owns 38,587 shares of the biopharmaceutical company’s stock worth $1,296,000 after buying an additional 5,477 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Pfizer by 3.1% in the second quarter. Oregon Public Employees Retirement Fund now owns 1,632,947 shares of the biopharmaceutical company’s stock worth $54,851,000 after buying an additional 49,400 shares during the last quarter. Legacy Private Trust Co. boosted its stake in shares of Pfizer by 3.8% in the second quarter. Legacy Private Trust Co. now owns 59,082 shares of the biopharmaceutical company’s stock worth $1,984,000 after buying an additional 2,150 shares during the last quarter. Winslow Evans & Crocker Inc. boosted its stake in shares of Pfizer by 22.4% in the second quarter. Winslow Evans & Crocker Inc. now owns 58,507 shares of the biopharmaceutical company’s stock worth $1,969,000 after buying an additional 10,709 shares during the last quarter. Finally, Cascade Investment Advisors Inc. boosted its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. 70.10% of the stock is currently owned by institutional investors.

Shares of Pfizer, Inc. (NYSE PFE) traded down 0.51% during trading on Friday, reaching $33.25. 12,928,473 shares of the company traded hands. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The stock has a market capitalization of $198.43 billion, a PE ratio of 24.32 and a beta of 1.00. The firm’s 50-day moving average is $33.40 and its 200-day moving average is $33.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. Pfizer’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 earnings per share. On average, equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. Pfizer’s dividend payout ratio is presently 94.12%.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (NYSE:PFE) Position Boosted by Regent Investment Management LLC” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/12/pfizer-inc-nysepfe-position-raised-by-regent-investment-management-llc-updated-updated-updated.html.

A number of brokerages recently commented on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their price target for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Finally, UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit